Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Interest Expense : ¥-35 Mil (TTM As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Tianjin Pharmaceutical Da Ren Tang Group's interest expense for the three months ended in Mar. 2024 was ¥ -7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-35 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Tianjin Pharmaceutical Da Ren Tang Group's Operating Income for the three months ended in Mar. 2024 was ¥ 371 Mil. Tianjin Pharmaceutical Da Ren Tang Group's Interest Expense for the three months ended in Mar. 2024 was ¥ -7 Mil. Tianjin Pharmaceutical Da Ren Tang Group's Interest Coverage for the quarter that ended in Mar. 2024 was 54.30. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tianjin Pharmaceutical Da Ren Tang Group Interest Expense Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Interest Expense Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.89

-0.01

-2.94

-10.27

-35.85

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-8.06	-8.95	-10.83	-8.02	-6.83

Tianjin Pharmaceutical Da Ren Tang Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-35 Mil.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tianjin Pharmaceutical Da Ren Tang Group's Interest Expense for the three months ended in Mar. 2024 was ¥-7 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥371 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ¥243 Mil.

Tianjin Pharmaceutical Da Ren Tang Group's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	371.106	/	-6.834
	=	54.30

The higher the ratio, the stronger the company's financial strength is.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Interest Expense

Traded in Other Exchanges

T14:Singapore

Address

No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193

Website

http://www.jydrt.com.cn

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines

No Headlines